172 related articles for article (PubMed ID: 25796502)
1. Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study.
Bergfelt E; Kozlowski P; Ahlberg L; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Åström M; Amini RM; Hallböök H
Med Oncol; 2015 Apr; 32(4):135. PubMed ID: 25796502
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Salah-Eldin M; Abousamra NK; Azzam H
Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
[TBL] [Abstract][Full Text] [Related]
3. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Ravandi F; Jorgensen JL; Thomas DA; O'Brien S; Garris R; Faderl S; Huang X; Wen S; Burger JA; Ferrajoli A; Kebriaei P; Champlin RE; Estrov Z; Challagundla P; Wang SA; Luthra R; Cortes JE; Kantarjian HM
Blood; 2013 Aug; 122(7):1214-21. PubMed ID: 23836561
[TBL] [Abstract][Full Text] [Related]
4. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
5. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
[TBL] [Abstract][Full Text] [Related]
7. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission.
Xue YJ; Suo P; Huang XJ; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Kong J; Zhang XH; Chen YH; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Cheng YF
Br J Haematol; 2020 Mar; 188(5):757-767. PubMed ID: 31725190
[TBL] [Abstract][Full Text] [Related]
8. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.
Ravandi F; Jorgensen JL; O'Brien SM; Jabbour E; Thomas DA; Borthakur G; Garris R; Huang X; Garcia-Manero G; Burger JA; Ferrajoli A; Wierda W; Kadia T; Jain N; Wang SA; Konoplev S; Kebriaei P; Champlin RE; McCue D; Estrov Z; Cortes JE; Kantarjian HM
Br J Haematol; 2016 Feb; 172(3):392-400. PubMed ID: 26492205
[TBL] [Abstract][Full Text] [Related]
11. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
12. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
13. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
Pemmaraju N; Kantarjian H; Jorgensen JL; Jabbour E; Jain N; Thomas D; O'Brien S; Wang X; Huang X; Wang SA; Konopleva M; Konoplev S; Kadia T; Garris R; Pierce S; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2017 Mar; 92(3):279-285. PubMed ID: 28052371
[TBL] [Abstract][Full Text] [Related]
14. Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.
Farahat N; Morilla A; Owusu-Ankomah K; Morilla R; Pinkerton CR; Treleaven JG; Matutes E; Powles RL; Catovsky D
Br J Haematol; 1998 Apr; 101(1):158-64. PubMed ID: 9576196
[TBL] [Abstract][Full Text] [Related]
15. Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
Huang A; Huang C; Tang G; Cheng H; Liu M; Ding J; Gong S; Chen Q; Zhang W; Yang J; Wang J; Hu X
Leuk Lymphoma; 2018 May; 59(5):1073-1083. PubMed ID: 28857648
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
17. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.
Eckert C; Hagedorn N; Sramkova L; Mann G; Panzer-Grümayer R; Peters C; Bourquin JP; Klingebiel T; Borkhardt A; Cario G; Alten J; Escherich G; Astrahantseff K; Seeger K; Henze G; von Stackelberg A
Leukemia; 2015 Aug; 29(8):1648-55. PubMed ID: 25748682
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of minimal residual disease monitoring to predict prognosis of adult patients with Ph-negative acute lymphoblastic leukemia.
Nagafuji K; Miyamoto T; Eto T; Ogawa R; Okumura H; Takase K; Kawano N; Miyazaki Y; Fujisaki T; Wake A; Ohno Y; Kurokawa T; Kamimura T; Takamatsu Y; Yokota S; Akashi K
Eur J Haematol; 2019 Sep; 103(3):164-171. PubMed ID: 31132205
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Giebel S; Bruggemann M; Doubek M; Foà R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Rambaldi A; Ribera JM; Schoonen M; Stieglmaier JM; Zugmaier G; Bassan R
Hematology; 2019 Dec; 24(1):337-348. PubMed ID: 30757960
[TBL] [Abstract][Full Text] [Related]
20. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
